See the DrugPatentWatch profile for kadcyla

Kadcyla, a medication used to treat certain types of breast cancer, has been granted market exclusivity for a specific period. However, the exact duration of this exclusivity is not explicitly stated in the information provided.

The US Food and Drug Administration (FDA) grants market exclusivity to incentivize and protect the investment made by drug manufacturers in the development of new drugs. This exclusivity period begins after a drug receives approval and lasts for a certain number of years, during which no generic versions of the drug can be approved [1].

For oncology drugs like Kadcyla, the exclusivity period can be extended by up to six months if the drug manufacturer conducts pediatric studies [2].

According to DrugPatentWatch.com, Kadcyla's market exclusivity is set to expire in 2029 [3]. However, it is important to note that this date may change due to various factors, such as patent extensions or legal challenges.

In summary, while the exact duration of Kadcyla's market exclusivity is not explicitly stated, it is expected to last until at least 2029, according to DrugPatentWatch.com [3].

Sources:
[1] US Food and Drug Administration. (n.d.). Exclusivity. Retrieved from https://www.fda.gov/drugs/development-approval-process-drugs/exclusivity
[2] US Food and Drug Administration. (n.d.). Pediatric Studies. Retrieved from https://www.fda.gov/drugs/development-approval-process-drugs/pediatric-studies
[3] DrugPatentWatch.com. (n.d.). Kadcyla (ado-trastuzumab emtansine) - Patent Expiration & Drug Sales. Retrieved from https://www.drugpatentwatch.com/patent/kadcyla-ado-trastuzumab-emtansine/